LAPTOP: Phase 1/2 Study in Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination with Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation.
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Gemcitabine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms LAPTOP
Most Recent Events
- 12 Mar 2025 Status changed from active, no longer recruiting to completed.
- 24 May 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 24 May 2024 Status changed from recruiting to active, no longer recruiting.